Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Silencing of MPP8 also decreased the expression of metastasis pathway-related proteins (N-cadherin and vimentin), and as well as the levels of anti-oncogene ZEB1, MET, and KRAS mRNA.
|
31692032 |
2020 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Our results show that the combination of trebananib with a MET kinase inhibitor significantly inhibits the spread of metastases, reduces infiltrating M2 type macrophages, and prolongs survival in our highly metastatic ccRCC PDX model, suggesting a potential use for this combination therapy in treating patients with ccRCC.
|
31582532 |
2020 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Considering the role of proto-oncogene c-Met (c-Met) in oncogenesis, we examined the effects of the metastasis suppressor, N-myc downstream regulated gene-1 (NDRG1), and two NDRG1-inducing thiosemicarbazone-based agents, Dp44mT and DpC, on c-Met expression in DU145 and Huh7 cells.
|
31744884 |
2020 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The oncogene MET into exosomes was identified from icotinib-resistant lung cancer cells, and this was also presented in exosomes in NSCLC patients diagnosed with cancer metastasis after icotinib treatment.
|
31606039 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In patients with c-MET-positive tumors, MTV and TLG were independent factors in predicting patient OS after correction by distant metastasis (hazards ratio = 1.014 and 1.002, respectively; P = 0.024 and 0.027, respectively), while these associations were not significant in patients with c-MET-negative tumors.
|
31395059 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
C-Met plays important roles in treatment resistance, tumor invasion, and metastasis.
|
30412912 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
These results highlighted the roles of AXL/MET in cancer growth and metastasis and further verified that the critical targets of DCC-2036 are AXL and MET, especially AXL.
|
30289981 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The hepatocyte growth factor receptor C-met plays an important role in cellular migration, which is crucial for many developmental processes as well as for cancer cell metastasis.
|
31287821 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In parallel, EA extract provokes differentiation to an epithelial phenotype "mesenchymal-to-epithelial transition: MET" which is the opposite of "epithelial-to-mesenchymal transition, EMT": an important event in cell invasion and metastasis.
|
29300111 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Our studies propose that the regulatory mechanisms of the HGF/MET-induced cascade pathway is mediated by FOSL2 in NSCLC metastasis and suggested that FOSL2 could potentially be employed as a prognostic biomarker and potential therapeutic target of NSCLC metastasis.
|
31807006 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Importantly, we found that KPNB1 could interact with MET to modulate cell proliferation and metastasis in CRC.
|
31629952 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Our data support the idea that simultaneous targeting of EGFR and MET could be a promising therapeutic strategy inhibiting not only tumor cell growth but also its metastasis.
|
31649529 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
HGF and its receptor MET play critical roles in liver carcinogenesis and metastasis, mainly dependent on the activity of receptor tyrosine kinase.
|
30786811 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Surprisingly, we found that targeting EWS tumors with HGF receptor neutralizing antibody (AMG102) in combination with GD2-specific, CAR-reengineered T-cell therapy synergistically inhibited primary tumor growth and establishment of metastatic disease in preclinical models.
|
31621900 |
2019 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Tyrosine protein kinase Met (MET) expression increases following VEGF inhibition, and inhibition of both has shown additive effects in controlling tumor growth and metastasis.
|
31171735 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
HGF/SF-MET signaling is equally crucial for growth and metastasis of a variety of human tumors, but resistance to small-molecule inhibitors of MET kinase develops rapidly and therapeutic antibody targeting remains challenging.
|
30930049 |
2019 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
MET gene amplification and protein over-expression are closely related to the invasion and metastasis, late stage and poor prognosis of gastric cancer.
|
31499745 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
[Corrigendum] AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.
|
30542697 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
A number of receptor tyrosine kinases (RTKs) including EGFR and MET have been reported to be involved in CMM metastasis and in the development of resistance to therapy, targeting the mitogen-activated protein kinase (MAPK pathway).
|
31506424 |
2019 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The results from these newly developed mouse models indicate a role for MET in hastening tumorigenesis and metastasis when combined with the loss of tumor suppressors.
|
30401749 |
2018 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
When aberrantly activated, MET and its stroma-secreted ligand HGF (Hepatocyte Growth Factor) concur to tumor onset, progression, and metastasis in solid tumors, thus representing a relevant target for cancer precision medicine.
|
30544501 |
2018 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
MET status should be re-evaluated in GC patients with liver metastasis, especially for metachronous metastasis.
|
29790169 |
2018 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
We also analyzed subgroups at high risk (prostate-specific antigen >20 ng/ml, RP Gleason score 8-10, or stage >pT3b), or very high risk of PCSM (biochemical recurrence in<2 yr [BCR2], or men who developed metastasis after RP [MET]).
|
28400167 |
2018 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
MET overexpression and chromosome 7 polysomy are positively correlated with higher Ki-67 index and higher grade and might have a high risk of local recurrence and metastasis.
|
30126419 |
2018 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The MET proto-oncogene (c-MET) participates in metastasis and is highly expressed in gastric cancer.
|
29494948 |
2018 |